The Center, which will be called the Holy Cross Hospital Lung CAre Center, a DxTx facility, will open in the fourth quarter of 2004 and will be closely aligned with the Holy Cross Cancer Institute.
Frank Sullivan, M.D., medical director of the Holy Cross Cancer Institute and former acting director of radiation oncology at the National Cancer Institute, stated: "Lung cancer continues to be responsible for 30 percent of all cancer deaths with no significant improvement in survival in the last four decades. We are excited to partner with DxTx Corporation to provide an integrated approach to the diagnosis and the treatment of early stage lung cancer. The ability to be the first institution in the country to offer non-invasive outpatient treatment using TIGRIS focused beam therapy in addition to traditional treatment methods will allow Holy Cross to remain a leader in lung cancer care."
Catherine Copertino, executive director of the Holy Cross Cancer Institute, added: "The Holy Cross Hospital Lung CAre Center will allow us to offer our community a low cost screening programme and to significantly reduce the burden of the disease through earlier diagnosis and treatment. We are excited about the opportunity to significantly strengthen our lung cancer programme by offering leading-edge technology to more people in our area."
"Lung cancer remains the leading cause of cancer deaths in the United States", stated James R. Doty, M.D., CEO of DxTx Corporation. "Only by diagnosing lung cancer early is there any realistic hope for cure. The DxTx LungCAre Center offers an integrated disease state management approach using an ultra-fast multi-slice CT scanner to screen patients and computer-aided detection to diagnose tumours."
"The Center will offer the latest in traditional treatment methods but also innovative proprietary technology for non-invasive treatment using TIGRIS image-guided focused beam therapy. The DxTx approach of creating DxTx LungCAre Centers throughout the United States, all connected by a scalable relational database and utilising the latest scientific breakthroughs to create diagnosis and treatment protocols, will allow DxTx and our partners to have a potentially profound impact on the manner in which lung cancer is diagnosed and treated", Dr. Doty explained.
TIGRIS focused beam therapy is a non-invasive image-guided radiation therapy system that will be used with a high output single energy linear accelerator and an inverse treatment planning programme to deliver hypofractionated Intensity Modulated Radiotherapy under stereotactic guidance to destroy tumours and other lesions without open surgery. TIGRIS is the only radiation treatment device using image-guidance technology and a six degrees-of-freedom robotic couch to track moving targets throughout the respiratory cycle while delivering multiple precisely modulated beams of radiation, thereby minimising injury to surrounding tissue.
Holy Cross Hospital is a 380-bed acute care facility. With more than 30.000 annual admissions, the hospital is the largest community hospital in Maryland and offers a full range of inpatient and outpatient speciality care services. Holy Cross Hospital is a member of the Association of American Medical College's Council of Teaching Hospitals. The Holy Cross Cancer Programme is accredited by the American College of Surgeons' Commission on Cancer as a teaching hospital cancer programme. Holy Cross has the largest inpatient cancer programme in the Maryland suburbs of Washington, D.C.
DxTx Corporation, a privately held corporation, is a disease state management company that develops proprietary integrated solutions to cancer care utilising the latest technologies in screening, diagnosis, staging, treatment and follow-up. The company in partnership with physician groups, hospitals and institutions creates disease specific oncology CAre Centers that are efficient, cost-effective and patient friendly.